• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Oculis Holding AG

    5/8/25 4:15:13 PM ET
    $OCS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OCS alert in real time by email
    6-K 1 q1_2025_6-k_fs_mda_pr.htm 6-K 6-K

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    FORM 6-K

     

    REPORT OF FOREIGN ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16

    OF THE SECURITIES EXCHANGE ACT OF 1934

    For the Month of May 2025

    (Commission File No. 001-41636)

    Oculis Holding AG

    (Translation of registrant's name into English)

    Bahnhofstrasse 20

    CH-6300

    Zug, Switzerland

    (Address of registrant’s principal executive office)

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

    Form 20-F ☒ Form 40-F ☐

     

     


    INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

     

    On May 8, 2025, Oculis Holding AG (the “Registrant”) announced its unaudited financial results for the three-month period ended March 31, 2025, which are further described in the Registrant’s Unaudited Condensed Consolidated Interim Financial Statements, Management’s Discussion and Analysis of Financial Condition and Results of Operations and press release, copies of which are attached hereto as Exhibits 99.1, 99.2 and 99.3, respectively, and are incorporated by reference herein.

     

    The information contained in this Form 6-K, including Exhibits 99.1 and 99.2 but excluding Exhibit 99.3, is hereby incorporated by reference into the Registrant’s Registration Statements on Form S-8 (File No. 333-271938) and Form F-3 (333-271063, 333-281798 and 333-278409).

     

     

    EXHIBIT INDEX

    Exhibit

    Description

    99.1

    Unaudited Condensed Consolidated Interim Financial Statements for the Three Months Ended March 31, 2025

    99.2

     

    Management’s Discussion and Analysis of Financial Condition and Results of Operations for the Three Months Ended March 31, 2025

    99.3

     

    Press release dated May 8, 2025

     

     


    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

     

     

     

     

     

     

     

     

    OCULIS HOLDING AG

     

     

     

     

    Date: May 8, 2025

     

    By:

    /s/ Sylvia Cheung

     

     

     

    Sylvia Cheung

    Chief Financial Officer

     


    Get the next $OCS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OCS

    DatePrice TargetRatingAnalyst
    12/5/2023$30.00Buy
    Chardan Capital Markets
    10/5/2023$35.00Buy
    Stifel
    6/14/2023$22.00Buy
    BofA Securities
    6/12/2023$28.00Buy
    H.C. Wainwright
    6/8/2023$58.00Outperform
    Robert W. Baird
    5/10/2023$23.00Buy
    Pareto
    4/28/2023$27.00Outperform
    Wedbush
    More analyst ratings

    $OCS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Oculis Reports Q1 2025 Financial Results and Provides Company Update

      The recent R&D Day (replay) showcased material progress across all three core assets and highlighted potential first-in-class neuroprotection treatment in neuro-ophthalmology, an area of high unmet medical need, thanks to Privosegtor's (OCS-05) positive results from the ACUITY trial in Acute Optic NeuritisOCS-01: DIAMOND Ph3 trials enrollment completed with over 800 patients randomized; topline results expected Q2 2026 for the first potential eye drop treatment for diabetic macular edema (DME)Licaminlimab (OCS-02) genotype-based development plan to drive a personalized medicine approach in dry eye disease (DED) aligned with FDA; first registrational trial initiation anticipated in 2H 2025Cas

      5/8/25 4:05:00 PM ET
      $OCS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oculis to Present at Upcoming May Investor Conferences

      ZUG, Switzerland, May 07, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis"), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced that Oculis will be attending and presenting at the following upcoming investor conferences: Bio€quity EuropeMay 12-14, 2025; Bruges, BelgiumCompany update by Riad Sherif, MD, Chief Executive Officer, on May 14 at 11am CET Bank of America Healthcare ConferenceMay 13-15, 2025; Las Vegas, USAFireside chat with Sylvia Cheung, Chief Financial Officer, on May 14 at 3pm PT H.C. Wainwright Annual BioConnect at NasdaqMay 20, 2025; New York,

      5/7/25 4:00:00 AM ET
      $OCS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oculis to Present its Innovative Late-Stage Pipeline Candidates at Upcoming Ophthalmology Conferences

      ZUG, Switzerland, May 01, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis"), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced upcoming presentations highlighting its innovative late-stage pipeline at Eyecelerator 2025, the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting and the Retina World Congress (RWC). The presentation of the DME AWARE Delphi Study interim results will highlight key areas of consensus on unmet needs in DME patient management among leading global experts. Further insights from Stage 1 of the Phase 3 DIAMOND progr

      5/1/25 4:00:00 AM ET
      $OCS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OCS
    Leadership Updates

    Live Leadership Updates

    See more
    • Virometix appoints Christina Ackermann as Chair and Tim Ramdeen as member of the Board

      Virometix AG, a privately held Swiss biotechnology company developing a new generation of fully synthetic vaccines to generate targeted and protective immune responses against infectious diseases and cancer today announces the appointment of Christina Ackermann as Chairwoman and Tim Ramdeen as a new member of its Board of Directors. Ms. Ackermann brings over 27 years of legal and management experience within the healthcare industries. Mr. Ramdeen has nearly a decade of experience in private equity, hedge fund investing, and capital markets. Christina Ackermann and Tim Ramdeen have led clinical and commercial companies through product development, growth, and commercialization while raising

      10/8/24 5:00:00 AM ET
      $ENTO
      $OCS
      $ONCO
      $VRNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oculis Announces Appointment of Daniel S. Char as Chief Legal Officer

      Mr. Char brings extensive experience in leading legal, compliance and corporate governance functions in successful biotech and medical device companiesThe appointment further expands Oculis' leadership team as the company advances its late-stage pipeline and prepares for commercial phase ZUG, Switzerland, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis"), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced the appointment of Daniel S. Char to the role of Chief Legal Officer, leading Oculis' legal, compliance and corporate governance functions. Mr. Char brings over 35 years of success in global legal leade

      10/2/24 4:00:00 AM ET
      $OCS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oculis Appoints Sharon Klier, M.D., M.S., M.P.H. as Chief Development Officer

      Dr. Klier brings significant experience in ophthalmology and drug development with a proven track record in U.S. FDA approvals, which will be instrumental as the company advances its late-stage pipelineAppointment further expands Oculis' executive leadership team and bolsters U.S. presence ZUG, Switzerland, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis"), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced the appointment of Dr. Sharon Klier, an executive leader with extensive experience in clinical development across early and late-stage programs, regulatory submissions, and approvals, to the role of Chie

      8/15/24 8:00:00 AM ET
      $OCS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OCS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Chardan Capital Markets initiated coverage on Oculis Holding AG with a new price target

      Chardan Capital Markets initiated coverage of Oculis Holding AG with a rating of Buy and set a new price target of $30.00

      12/5/23 8:03:01 AM ET
      $OCS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stifel initiated coverage on Oculis Holding AG with a new price target

      Stifel initiated coverage of Oculis Holding AG with a rating of Buy and set a new price target of $35.00

      10/5/23 7:50:21 AM ET
      $OCS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BofA Securities initiated coverage on Oculis Holding AG with a new price target

      BofA Securities initiated coverage of Oculis Holding AG with a rating of Buy and set a new price target of $22.00

      6/14/23 8:10:40 AM ET
      $OCS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $OCS
    Financials

    Live finance-specific insights

    See more

    $OCS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $OCS
    SEC Filings

    See more
    • Oculis Announces Positive Top Line Results from DIAMOND Stage 1 Phase 3 Trial in Diabetic Macular Edema with OCS-01 Eye Drops

      DIAMOND trial in Diabetic Macular Edema (DME) with topical OCS-01 met its stage 1 objective of validating the loading and maintenance dosing regimen designed to optimize OCS-01 efficacy potential with robust statistical significancePrimary efficacy endpoint of mean change in Best Corrected Visual Acuity (BCVA) versus baseline at Week 6 showed statistically significant increase in visual acuity in the OCS-01 arm compared to vehicle armStatistically significant secondary endpoints showed higher percentage of patients achieving ≥15-letter improvement in BCVA and better improvement in retinal thickness in the OCS-01 arm versus vehicle armOCS-01 was well-tolerated with no unexpected adverse event

      5/22/23 6:30:00 AM ET
      $OCS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oculis to Host Conference Call on April 13, 2023 to Discuss Late-Stage Pipeline and Near-Term Clinical Milestones

      ZUG, Switzerland and BOSTON, April 04, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS) ("Oculis"), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announces that it will host a virtual conference call and webcast to present an overview of its late-stage pipeline and discuss expected near-term clinical milestones on Thursday, April 13 from 8:00am-9:00am ET / 13:00-14:00 BST / 14:00-15:00 CET. Oculis is focused on becoming a leading global ophthalmic biopharmaceutical company with product candidates to address areas of significant medical needs, including diabetic macular edema (DME), dry eye disease (DED), and neuro-retina indica

      4/4/23 7:00:00 AM ET
      $OCS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Oculis Holding AG

      SC 13G - Oculis Holding AG (0001953530) (Subject)

      12/9/24 9:43:55 PM ET
      $OCS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Oculis Holding AG

      SC 13G/A - Oculis Holding AG (0001953530) (Subject)

      11/7/24 4:15:49 PM ET
      $OCS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Oculis Holding AG

      6-K - Oculis Holding AG (0001953530) (Filer)

      5/8/25 4:15:13 PM ET
      $OCS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Oculis Holding AG

      6-K - Oculis Holding AG (0001953530) (Filer)

      4/15/25 4:05:24 PM ET
      $OCS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 20-F filed by Oculis Holding AG

      20-F - Oculis Holding AG (0001953530) (Filer)

      3/11/25 4:35:27 PM ET
      $OCS
      Biotechnology: Pharmaceutical Preparations
      Health Care